Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2014 1
2015 4
2016 3
2017 3
2018 5
2019 3
2020 5
2021 6
2022 15
2023 6
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL.
Qi Y, Zhao M, Hu Y, Wang Y, Li P, Cao J, Shi M, Tan J, Zhang M, Xiao X, Xia J, Ma S, Qiao J, Yan Z, Li H, Pan B, Sang W, Li D, Li Z, Zhou J, Huang H, Liang A, Zheng J, Xu K. Qi Y, et al. Among authors: li h. Blood. 2022 Jun 9;139(23):3376-3386. doi: 10.1182/blood.2021013733. Blood. 2022. PMID: 35338773 Free PMC article. Clinical Trial.
Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma.
Wang Y, Cao J, Gu W, Shi M, Lan J, Yan Z, Jin L, Xia J, Ma S, Liu Y, Li H, Pan B, Chen W, Fei X, Wang C, Xie X, Yu L, Wang G, Li H, Jing G, Cheng H, Zhu F, Sun H, Sang W, Li D, Li Z, Zheng J, Xu K. Wang Y, et al. Among authors: li h. J Clin Oncol. 2022 Jul 10;40(20):2246-2256. doi: 10.1200/JCO.21.01676. Epub 2022 Mar 25. J Clin Oncol. 2022. PMID: 35333600 Clinical Trial.
Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ Trial.
Xia J, Li H, Yan Z, Zhou D, Wang Y, Qi Y, Cao J, Li D, Cheng H, Sang W, Zhu F, Sun H, Chen W, Qi K, Yan D, Qiu T, Qiao J, Yao R, Liu Y, Wang X, Zhang Y, Peng S, Huang CH, Zheng J, Li Z, Chang AH, Xu K. Xia J, et al. Among authors: li h. J Clin Oncol. 2023 May 10;41(14):2583-2593. doi: 10.1200/JCO.22.01824. Epub 2023 Mar 7. J Clin Oncol. 2023. PMID: 36881785 Free PMC article. Clinical Trial.
Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial.
Zhou D, Sun Q, Xia J, Gu W, Qian J, Zhuang W, Yan Z, Cheng H, Chen W, Zhu F, Qi K, Li D, Sang W, Zhu L, Ma S, Li H, Zhang H, Qiu T, Yan D, Zhang Y, Peng S, Chang AH, Xu K, Li Z. Zhou D, et al. Among authors: li h. Lancet Haematol. 2024 Jul 23:S2352-3026(24)00176-5. doi: 10.1016/S2352-3026(24)00176-5. Online ahead of print. Lancet Haematol. 2024. PMID: 39059405
Efficacy and safety of CD19-specific CAR-T cell-based therapy in secondary central nervous system lymphoma.
Zhang H, Yan Z, Wang Y, Qi Y, Hu Y, Li P, Cao J, Zhang M, Xiao X, Shi M, Xia J, Ma S, Qiao J, Li H, Pan B, Qi K, Cheng H, Sun H, Zhu F, Sang W, Li D, Li Z, Zheng J, Zhao M, Liang A, Huang H, Xu K. Zhang H, et al. Among authors: li h. Front Immunol. 2022 Aug 19;13:965224. doi: 10.3389/fimmu.2022.965224. eCollection 2022. Front Immunol. 2022. PMID: 36059496 Free PMC article.
50 results